The expression of MMP-2, MMP-7, MMP-9, and TIMP-1 in chronic rhinosinusitis and nasal polyposis

Otolaryngology - Head and Neck Surgery

Volumn 139, Issue 2, 2008, Pages 211-215

  Can, Ilknur Haberal ^a   Ceylan, Kursat ^a   Caydere, Muzaffer ^a   Samim, Ethem Erdal ^a   Ustun, Huseyin ^a   Karasoy, Durdu Sertkaya ^b  

^a MINISTRY OF HEALTH   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MATRILYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; EAR NOSE THROAT SURGERY; ENDOSCOPIC SURGERY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NOSE POLYP; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHINOSINUSITIS;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NASAL POLYPS; PROSPECTIVE STUDIES; SINUSITIS; STATISTICS, NONPARAMETRIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 47549116172     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otohns.2008.04.032     Document Type: Article

References (19)

1. Watelet J.B., Bachert C., Claeys C., et al. Matrix metalloproteinases MMP-7, MMP-9 and their tissue inhibitor TIMP-1: expression in chronic sinusitis vs. nasal polyposis. Allergy 59 (2004) 54-60
2. Lee Y.M., Kim S.S., Kim H., et al. Eosinophil inflammation of nasal polyp tissue: relationships with matrix metalloproteinases, tissue inhibitor of metalloproteinase-1, and transforming growth factor β1. J Korean Med Sci 18 (2003) 97-102
3. Santana A., Medina C., Paz-Cabrera M.C., et al. Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice. World J Gastroenterol 12 40 (2006) 6464-6472
4. Yozhuzaki H., Sato H., and Furukawa M. Recent advances in the regulation of matrix metalloproteinase 2 activation: from basic research to clinical implication (review). Oncol Rep 9 (2002) 607-611
5. Profita M., Gagliardo R., Di Giorgi R., et al. In vitro effects of flunisolide on MMP-9, TIMP-1, fibronectin, TGF-B1 release and apoptosis in sputum cells freshly isolated from mild to moderate asthmatics. Allergy 59 (2004) 927-932
6. Miller T.L., Touch S.M., and Shaffer T.H. Matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase expression profiles in tracheal aspirates do not adequately reflect tracheal or lung tissue profiles in neonatal respiratory distress: observations from an animal model. Pediatr Crit Care Med 7 1 (2006) 63-69
7. Chen P., Farivar A.S., Mulligan M.S., et al. Tissue inhibitor of metalloproteinase 1 deficiency abrogates obliterative airway disease after heterotopic tracheal transplantation. Am J Respir Cell Mol Biol 34 (2006) 464-472
8. Strup-Perrot C., Vozenin-Brotons M.C., Vandamme M., et al. Expression and activation of MMP-2, 3, 9, 14 are induced in rat colon after abdominal X irradiation. Scand J Gastroenterol 41 (2006) 60-70
9. Mercer P.F., Shute J.K., Bhowmik A., et al. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res 6 (2005) 151-159
10. Misugi F., Sumi T., Nobeyama H., et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis. Int J Mol Med 16 (2005) 541-546
11. Ko F.W.S., Diba C., Hons B., et al. A comparison of airway and serum matrix metalloproteinase 9 activity among normal subjects, asthmatic patients, and patients with asthmatic mucus hyper secretion. Chest 127 (2005) 1919-1927
12. Molykutty J., Jaworsky C., Chen Z., et al. Matrix metalloproteinases are down-regulated in rat lenses exposed to oxidative stress. Exp Eye Res 79 (2004) 839-846
13. Lechapt-Zalcman E., Coste A., d'Ortho M.P., et al. Increased expression of matrix metalloproteinase-9 in nasal polyps. J Pathol 193 (2001) 233-241
14. Hoekstra R., Eskens F.A.L.M., and Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist 6 5 (2001) 415-427
15. French J.J., Midwinter M.J., Bennett M.K., et al. A matrix metalloproteinase inhibitor to treat unresectable cholangiocarcinoma. HPB 7 (2005) 289-291
16. Inouye K., Oneda H., Muta Y., et al. Inhibitory effects of green tea catechins and lignans on the activity of human matrix metalloproteinase 7 (MMP 7) and insights into their structure-activity relationship. J Thromb Haemost 4 1 (2006) 125-125
17. Cho H.J., Lee T.S., Park J.B., et al. Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP 2 and MMP 9 expression. Biochem Mol Biol 40 6 (2007) 1069-1076 Nov 30
18. Barnett J.M., McCollum G.W., Fowler J.A., et al. Pharmacologic and genetic manipulation of MMP 2 and 9 affects retinal neovascularization in rodent models of OIR. Invest Ophthalmol Vis Sci 48 (2007) 907-915
19. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 13 3 (2007) 333-346